Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation.

Clinical Trial Description

Migraine is a common chronic neurological disorder characterized by recurrent disabling episodes of moderate to severe headache accompanied by nausea, vomiting, photophobia, and phonophobia. Acute pharmacologic therapy for migraine aims to terminate the attack or reduce its severity. Analgesics are commonly used or, if these are ineffective, triptans. Since triptans are contraindicated in patients with coronary artery disease, uncontrolled hypertension, and cerebrovascular disease alternative medications are required for patients where simple analgesics do not work. COL-144 has no vasoconstrictor activity at clinically relevant concentrations and might meet this need. COL-144 was effective when given intravenously in a placebo-controlled dose-ranging study. This study investigates which dose of oral COL-144 is effective in the in acute treatment of migraine headache. ;

Study Design

Related Conditions & MeSH terms

Migraine Disorders

Clinical Trial Details

NCT number	NCT00883051
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 2
Start date	July 2009
Completion date	February 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01432379` - BOTOX® Prophylaxis in Patients With Chronic Migraine
Completed	`NCT04084314` - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study	Phase 4
Recruiting	`NCT05048914` - Migraine Abortive Treatment
Completed	`NCT03662295` - Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
Completed	`NCT02766517` - Biomarker Study in Participants With Migraine	Early Phase 1
Completed	`NCT00963937` - Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents	Phase 3
Not yet recruiting	`NCT03632928` - Day to Day Variation of Pressure Pain Threshold and Muscle Hardness
Completed	`NCT02559895` - A Multicenter Assessment of ALD403 in Frequent Episodic Migraine	Phase 3
Completed	`NCT01435941` - Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine	N/A
Completed	`NCT00743015` - Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks	Phase 1
Completed	`NCT01376141` - Drug Use Investigation for IMIGRAN Tablet	N/A
Completed	`NCT02183688` - Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients	Phase 3
Completed	`NCT06061588` - "Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches"	N/A
Completed	`NCT03588364` - The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine	N/A
Completed	`NCT04091321` - Association Between Chronic Headache and Back Pain With Childbirth
Completed	`NCT00385008` - TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine	Phase 3
Active, not recruiting	`NCT05888298` - Proximal and Distal Approach GON RFT in Migraine	N/A
Completed	`NCT03435185` - Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients	N/A
Recruiting	`NCT06459635` - Migraine Attack Pain Phase Prediction Study
Completed	`NCT02565186` - An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine	Phase 3